AstraZeneca’s FLAURA2 Phase III trial showed favourable trend in EGFR-mutated advanced lung cancer
Combination shows consistent benefit across prespecified post-progression outcomes
Combination shows consistent benefit across prespecified post-progression outcomes
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
Proprietary implant-to-implant (i2i) device technology is used for communication between two implanted leadless pacemakers to regulate the heart rate
Subscribe To Our Newsletter & Stay Updated